288 related articles for article (PubMed ID: 26222073)
1. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.
Dvorak HF
Cancer J; 2015; 21(4):237-43. PubMed ID: 26222073
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.
Nagy JA; Dvorak HF
Clin Exp Metastasis; 2012 Oct; 29(7):657-62. PubMed ID: 22692562
[TBL] [Abstract][Full Text] [Related]
3. VEGF as a key mediator of angiogenesis in cancer.
Carmeliet P
Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
[TBL] [Abstract][Full Text] [Related]
4. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
5. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.
Sitohy B; Nagy JA; Jaminet SC; Dvorak HF
Cancer Res; 2011 Nov; 71(22):7021-8. PubMed ID: 21937680
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
7. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
Sitohy B; Nagy JA; Dvorak HF
Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695
[TBL] [Abstract][Full Text] [Related]
9. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of the tumor vasculature.
Nagy JA; Chang SH; Shih SC; Dvorak AM; Dvorak HF
Semin Thromb Hemost; 2010 Apr; 36(3):321-31. PubMed ID: 20490982
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition.
Nagy JA; Brown LF; Senger DR; Lanir N; Van de Water L; Dvorak AM; Dvorak HF
Biochim Biophys Acta; 1989 Feb; 948(3):305-26. PubMed ID: 2465781
[TBL] [Abstract][Full Text] [Related]
13. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
14. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
15. Tumors: wounds that do not heal-redux.
Dvorak HF
Cancer Immunol Res; 2015 Jan; 3(1):1-11. PubMed ID: 25568067
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor as a therapeutic target in cancer.
Bergsland EK
Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenesis, anti-VEGF(R) and outlook.
Petersen I
Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
20. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease.
Brown LF; Dvorak AM; Dvorak HF
Am Rev Respir Dis; 1989 Oct; 140(4):1104-7. PubMed ID: 2478057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
